Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Plasma cell 1

Conditions

Multiple Myeloma 2123Neoplasms, Plasma Cell 505Lymphoma 355Lymphoma, Non-Hodgkin 334Hodgkin Disease 329Leukemia, Lymphocytic, Chronic, B-Cell 307Precursor Cell Lymphoblastic Leukemia-Lymphoma 299Leukemia 290Leukemia, Myeloid, Acute 270Myelodysplastic Syndromes 263Lymphoma, Mantle-Cell 228Lymphoma, Follicular 224Lymphoma, Large B-Cell, Diffuse 216Lymphoma, B-Cell, Marginal Zone 206Burkitt Lymphoma 201Recurrence 188Myeloproliferative Disorders 182Lymphoma, Large-Cell, Immunoblastic 182Immunoglobulin Light-chain Amyloidosis 163Primary Myelofibrosis 153Leukemia, Myeloid, Chronic-Phase 152Leukemia, Myeloid, Accelerated Phase 143Lymphoma, T-Cell, Cutaneous 140Leukemia, Myelomonocytic, Chronic 133Blast Crisis 131Mycosis Fungoides 126Sezary Syndrome 125Congenital Abnormalities 122Waldenstrom Macroglobulinemia 121Leukemia, Hairy Cell 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Plasmablastic Lymphoma × Plasma cell × Clear all
NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1 Not yet recruiting
27 enrolled
LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡